Exploring melanoma shifts: a two-decade analysis in New Zealand.

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL

NEW ZEALAND MEDICAL JOURNAL Pub Date : 2024-06-07 DOI:10.26635/6965.6430

Daniel Wen, Jack S Pullman, Avinash Sharma, Bert van der Werf, Richard C W Martin

{"title":"Exploring melanoma shifts: a two-decade analysis in New Zealand.","authors":"Daniel Wen, Jack S Pullman, Avinash Sharma, Bert van der Werf, Richard C W Martin","doi":"10.26635/6965.6430","DOIUrl":null,"url":null,"abstract":"Aims: New Zealand melanoma incidence rates are amongst the highest in the world. The study aims to provide information on the incidence of cutaneous melanoma in New Zealand from 2000 to 2022.Methods: De-identified data were extracted from the New Zealand Cancer Registry using the ICD-10 code for malignant melanoma (C34) and melanoma in situ (MIS) (D03) from 2000 to 2022. Statistical analysis was performed to calculate melanoma incidence rates.Results: Invasive melanoma (IM) incidence rates demonstrated an increasing trend from 2000 to 2008 (+1.10 per 100,000 person-years per year), followed by an inflection point at 2008 and then a decreasing trend from 2008 to 2022 (-0.28 per 100,000 person-years per year), which was not statistically different from zero/no change. MIS incidence increased from 30.3 to 72.1 per 100,000 person-years between 2000 and 2022.Conclusions: The incidence of IM in New Zealand has plateaued in the last decade and was associated with an increase in MIS incidence over the same period. While this trend is encouraging, further research is required to investigate whether there is an actual decline in IM incidence.","PeriodicalId":48086,"journal":{"name":"NEW ZEALAND MEDICAL JOURNAL","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEW ZEALAND MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26635/6965.6430","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: New Zealand melanoma incidence rates are amongst the highest in the world. The study aims to provide information on the incidence of cutaneous melanoma in New Zealand from 2000 to 2022.

Methods: De-identified data were extracted from the New Zealand Cancer Registry using the ICD-10 code for malignant melanoma (C34) and melanoma in situ (MIS) (D03) from 2000 to 2022. Statistical analysis was performed to calculate melanoma incidence rates.

Results: Invasive melanoma (IM) incidence rates demonstrated an increasing trend from 2000 to 2008 (+1.10 per 100,000 person-years per year), followed by an inflection point at 2008 and then a decreasing trend from 2008 to 2022 (-0.28 per 100,000 person-years per year), which was not statistically different from zero/no change. MIS incidence increased from 30.3 to 72.1 per 100,000 person-years between 2000 and 2022.

Conclusions: The incidence of IM in New Zealand has plateaued in the last decade and was associated with an increase in MIS incidence over the same period. While this trend is encouraging, further research is required to investigate whether there is an actual decline in IM incidence.

查看原文本刊更多论文

探索黑色素瘤的转变：新西兰二十年的分析。

目的：新西兰的黑色素瘤发病率位居世界前列。本研究旨在提供2000年至2022年新西兰皮肤黑色素瘤发病率的相关信息：方法：从新西兰癌症登记处提取去身份化数据，使用恶性黑色素瘤（C34）和原位黑色素瘤（MIS）（D03）的 ICD-10 编码，从 2000 年到 2022 年进行统计分析。统计分析用于计算黑色素瘤发病率：侵袭性黑色素瘤（IM）发病率在2000年至2008年期间呈上升趋势（每10万人/年+1.10），2008年出现拐点，2008年至2022年呈下降趋势（每10万人/年-0.28），与零/无变化无统计学差异。2000年至2022年间，MIS发病率从每10万人年30.3例上升至72.1例：结论：在过去十年中，新西兰的IM发病率趋于平稳，同期MIS发病率也有所上升。虽然这一趋势令人鼓舞，但仍需进一步研究 IM 发病率是否真正下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NEW ZEALAND MEDICAL JOURNAL MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

23.50%

发文量

229